
Samsung Biologics Granted Terra Carta Seal
Award given in recognition of CDMO’s commitment to promoting sustainable future
Coming off its
Samsung is one of the 19 companies to have been awarded the 2022 Terra Carta Seal. The company affirmed its commitment to achieving net zero greenhouse gas emissions across its direct operations and supply chain by 2050 or earlier, as part of its global response to climate change.
“We are honored to be recognized with the Terra Carta Seal by the Sustainable Markets Initiative for Samsung Biologics’ contribution in working alongside our industry peers for this global effort,” says John Rim, CEO and president of Samsung Biologics. “Healthcare is at a pivotal moment, and through our collaborative efforts, we can contribute to shaping climate-resilient practices to influence and help shape policy across the pharmaceutical and healthcare sectors.”
Read more about the CDMO’s award
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.